论文部分内容阅读
目的:分析遵循“等效均匀剂量优化法”的调强放疗在肺癌患者中的应用效果。方法:82例非小细胞肺癌患者按照随机数表法分为观察组及对照组,对照组接受常规放疗,观察组接受遵循“等效均匀剂量优化法”的调强放疗。对比两组治疗效果及生存期、血管相关因子及凝血功能、炎症因子水平等差异。结果:观察组治疗后有效率高于对照组,无进展生存期及中位总生存期均长于对照组(P<0.05);观察组治疗后的血清VEGF、HIF-α水平低于对照组;D-D、TT、PT、APTT、FIB水平也低于对照组(P<0.05);观察组治疗后血清TNF-α、CRP、PCT水平值低于同一时间点的对照组(P<0.05);观察组接受治疗后的血清M2-PK、CA125、CEA、SCC值均明显低于对照组(P<0.05)。结论:肺癌患者接受遵循“等效均匀剂量优化法”的调强放疗,可以提升治疗效果并延长生存时间,在抑制肿瘤恶性生物学行为的同时优化微炎症环境,具有积极的临床意义。
OBJECTIVE: To analyze the application of intensity modulated radiotherapy following lung cancer with “Equal Uniform Dosage Optimization Method”. Methods: Eighty - two non - small cell lung cancer patients were divided into observation group and control group according to random number table method. The control group received conventional radiotherapy. The observation group received IMRT following the “equivalent uniform dose optimization method”. Compare the two groups of treatment and survival, vascular factors and coagulation, inflammatory cytokines levels and other differences. Results: The effective rate of the observation group was higher than that of the control group, and the progression-free survival and median overall survival were longer than those of the control group (P <0.05). The levels of serum VEGF and HIF-α in the observation group were lower than those in the control group. The levels of DD, TT, PT, APTT and FIB in the observation group were also lower than those in the control group (P <0.05). The levels of TNF-α, CRP and PCT in the observation group were lower than those in the control group at the same time point The serum levels of M2-PK, CA125, CEA and SCC in the treatment group were significantly lower than those in the control group (P <0.05). CONCLUSIONS: Patients with lung cancer undergoing intensity modulated radiotherapy following the equivalent uniform dose optimization method can improve the therapeutic effect and prolong the survival time, and optimize the micro-inflammatory environment while inhibiting the malignant biological behavior of the tumor, which has a positive clinical significance.